Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cadrenal Therapeutics, Inc. (CVKD)
NASDAQ:CVKD
RESEARCH TOOLSreports
Holding CVKD?
Track your performance easily
CVKD Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$5.40 - $32.55
Previous Close$7.36
Volume41.63K
Average Volume (3M)15.67K
Market Cap
$7.85M
Enterprise Value$7.86M
Total Cash (Recent Filing)$0.00
Total Debt (Recent Filing)$8.80K
Price to Earnings (P/E)―
Beta1.11
Next Earnings
Nov 07, 2024EPS Estimate
-$1.8Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.31
Shares Outstanding1,067,231
10 Day Avg. Volume53,952
30 Day Avg. Volume15,671
Standard Deviation0.45
R-Squared0.02
Alpha-0.05
Financial Highlights & Ratios
Price to Book (P/B)1.24
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-35.73
Enterprise Value/Ebitda-0.59
Forecast
1Y Price Target
$3.00Price Target Upside-59.24% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Cadrenal Therapeutics, Inc. News
PremiumCompany Announcements
Cadrenal Therapeutics Partners with Abbott on Cardiac Trial
PremiumCompany Announcements
Cadrenal Therapeutics Enhances Incentives and Adjusts Stock Plan
Bulls Say, Bears Say
Bulls Say
Anticoagulation DrugsThe growing visibility and strength of time in therapeutic range (TTR) for anticoagulation drugs and beyond is something that should factor importantly into upcoming considerations.
Clinical TrialsCadrenal is actively developing an LVAD study protocol to advance into Phase 3 trials.
Collaborative EffortsCadrenal announced the initiation of a collaborative effort with Abbott to advance tecarfarin for patients with LVADs.
Bears Say
Cash ReservesCadrenal ended the quarter with $5 million in cash.
EarningsCadrenal announced 2Q24 financial results, posting EPS of ($0.15) compared to our estimate of ($0.12) and consensus of ($0.08).
Financial RiskThe company faces increased financial risk considering the upcoming expenses for the planned Phase 3 ACTOR AF trial and the Phase 3 trials in left ventricular assist device (LVAD) patients.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CVKD FAQ
What was Cadrenal Therapeutics, Inc.’s price range in the past 12 months?
Cadrenal Therapeutics, Inc. lowest stock price was $5.40 and its highest was $32.55 in the past 12 months.
What is Cadrenal Therapeutics, Inc.’s market cap?
Currently, no data Available
When is Cadrenal Therapeutics, Inc.’s upcoming earnings report date?
Cadrenal Therapeutics, Inc.’s upcoming earnings report date is Nov 07, 2024 which is in 74 days.
How were Cadrenal Therapeutics, Inc.’s earnings last quarter?
Cadrenal Therapeutics, Inc. released its earnings results on Aug 07, 2024. The company reported -$2.25 earnings per share for the quarter, missing the consensus estimate of -$1.275 by -$0.975.
Is Cadrenal Therapeutics, Inc. overvalued?
According to Wall Street analysts Cadrenal Therapeutics, Inc.’s price is currently Overvalued.
Does Cadrenal Therapeutics, Inc. pay dividends?
Cadrenal Therapeutics, Inc. does not currently pay dividends.
What is Cadrenal Therapeutics, Inc.’s EPS estimate?
Cadrenal Therapeutics, Inc.’s EPS estimate is -$1.8.
How many shares outstanding does Cadrenal Therapeutics, Inc. have?
Cadrenal Therapeutics, Inc. has 1,067,231 shares outstanding.
What happened to Cadrenal Therapeutics, Inc.’s price movement after its last earnings report?
Cadrenal Therapeutics, Inc. reported an EPS of -$2.25 in its last earnings report, missing expectations of -$1.275. Following the earnings report the stock price went up 4.839%.
Which hedge fund is a major shareholder of Cadrenal Therapeutics, Inc.?
Currently, no hedge funds are holding shares in CVKD
---
Cadrenal Therapeutics, Inc. Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.00 (-59.24% Downside)
$3.00 (-59.24% Downside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-36.27%
12-Months-Change
Fundamentals
Return on Equity
-174.01%
Trailing 12-Months
Asset Growth
53.33%
Trailing 12-Months
Company Description
Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.
---
CVKD Stock 12 Month Forecast
Average Price Target
$3.00
▼(-59.24% Downside)
Technical Analysis
Best Analysts Covering CVKD
1 Year
1 Year Success Rate
1/5 ratings generated profit
1 Year Average Return
-8.72%
reiterated a buy rating 17 days ago
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 20.00% of your transactions generating a profit, with an average return of -8.72% per trade.
---